Symbols / ELUT Stock $1.06 -8.62% Elutia Inc.

Healthcare • Medical Devices • United States • NCM
ELUT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Dr. C. Randal Mills Ph.D.
Exch · Country NCM · United States
Market Cap 46.86M
Enterprise Value 11.66M
Income -15.87M
Sales 12.29M
FCF (ttm) -25.10M
Book/sh 0.65
Cash/sh 0.85
Employees 25
Insider 10d —
IPO Oct 08, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.96
PEG —
P/S 3.81
P/B 1.64
P/C —
EV/EBITDA -0.68
EV/Sales 0.95
Quick Ratio 1.51
Current Ratio 2.22
Debt/Eq 14.24
LT Debt/Eq —
EPS (ttm) -0.65
EPS next Y -1.10
EPS Growth —
Revenue Growth 16.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-14
Earnings (prior) 2026-05-14
ROA -23.37%
ROE —
ROIC —
Gross Margin 53.66%
Oper. Margin -167.87%
Profit Margin 4.34%
Shs Outstand 44.21M
Shs Float 24.89M
Insider Own 3.56%
Instit Own 45.72%
Short Float 0.33%
Short Ratio 1.81
Short Interest 126.20K
52W High 2.64
vs 52W High -59.85%
52W Low 0.50
vs 52W Low 112.00%
Beta 0.76
Impl. Vol. —
Rel Volume 1.80
Avg Volume 129.28K
Volume 233.32K
Target (mean) $5.00
Tgt Median $5.00
Tgt Low $5.00
Tgt High $5.00
# Analysts 1
Recom None
Prev Close $1.16
Price $1.06
Change -8.62%
About

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.00
Mean price target
2. Current target
$1.06
Latest analyst target
3. DCF / Fair value
$-10.22
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.06
Low
$5.00
High
$5.00
Mean
$5.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-10 main Lake Street Buy → Buy $6
2025-05-09 main Lake Street Buy → Buy $8
2025-03-07 reit Cantor Fitzgerald Overweight → Overweight $8
2024-11-15 reit Cantor Fitzgerald Overweight → Overweight $10
2024-09-06 reit Cantor Fitzgerald Overweight → Overweight $10
2024-08-08 main Cantor Fitzgerald Overweight → Overweight $10
2024-06-21 main Lake Street Buy → Buy $10
2024-06-20 main Cantor Fitzgerald Overweight → Overweight $11
2024-06-18 main Cantor Fitzgerald Overweight → Overweight $11
2024-05-10 main Cantor Fitzgerald Overweight → Overweight $5
2023-11-14 main Cantor Fitzgerald Overweight → Overweight $6
2023-09-28 init Lake Street — → Buy $3
2023-09-26 reit Cantor Fitzgerald Overweight → Overweight $8
2023-09-19 reit Cantor Fitzgerald Overweight → Overweight $8
News
RSS: Latest ELUT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-10 MILLS CHARLES RANDAL Chief Executive Officer — 27,084 — —
2026-03-10 FERGUSON MATTHEW B Chief Financial Officer — 12,500 — —
2026-03-10 WILLIAMS MICHELLE LEROUX Officer — 12,500 — —
2026-01-30 NEELS GUIDO J Director — 20,000 $1.04 $20,800
2026-01-30 RAKIN KEVIN L Director and Beneficial Owner of more than 10% of a Class of Security — 70,000 $1.06 $74,200
2026-01-29 NEELS GUIDO J Director — 30,000 $1.06 $31,800
2025-12-17 MAKES BRIGID A Director — 25,000 $0.52 $13,000
2025-12-17 RAKIN KEVIN L Director and Beneficial Owner of more than 10% of a Class of Security — 50,000 $0.52 $25,995
2025-12-17 MILLS CHARLES RANDAL Chief Executive Officer — 3,000 $0.51 $1,530
2025-12-17 FERGUSON MATTHEW B Chief Financial Officer — 60,000 $0.53 $31,800
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
12.29
-15.03%
14.47
-41.54%
24.75
+3.76%
23.85
Operating Revenue
12.29
-15.03%
14.47
-41.54%
24.75
+3.76%
23.85
Cost Of Revenue
5.70
-26.51%
7.75
-43.38%
13.69
+12.14%
12.21
Reconciled Cost Of Revenue
5.70
-26.51%
7.75
-43.38%
13.69
+12.14%
12.21
Gross Profit
6.60
-1.77%
6.71
-39.25%
11.05
-5.03%
11.64
Operating Expense
25.01
-4.03%
26.06
-17.51%
31.59
-24.11%
41.63
Research And Development
4.16
+38.86%
3.00
-31.85%
4.40
-43.07%
7.73
Selling General And Administration
20.84
-9.61%
23.06
-15.19%
27.19
-19.79%
33.90
Selling And Marketing Expense
5.76
+15.58%
4.99
-61.89%
13.09
-26.68%
17.85
General And Administrative Expense
15.08
-16.56%
18.07
+28.14%
14.10
-12.13%
16.05
Other Gand A
15.08
-16.56%
18.07
+28.14%
14.10
-12.13%
16.05
Total Expenses
30.70
-9.19%
33.81
-25.33%
45.28
-15.89%
53.84
Operating Income
-18.41
+4.82%
-19.34
+5.81%
-20.54
+31.52%
-29.99
Total Operating Income As Reported
-26.91
+12.38%
-30.71
-0.61%
-30.53
+13.25%
-35.19
EBITDA
-15.63
+61.87%
-40.99
-29.39%
-31.68
-16.05%
-27.30
Normalized EBITDA
-20.55
-39.42%
-14.74
+16.00%
-17.55
+20.59%
-22.10
Reconciled Depreciation
2.79
-19.30%
3.45
-7.92%
3.75
+0.40%
3.73
EBIT
-18.41
+58.57%
-44.44
-25.44%
-35.42
-14.16%
-31.03
Total Unusual Items
4.92
+118.76%
-26.25
-85.76%
-14.13
-171.71%
-5.20
Total Unusual Items Excluding Goodwill
4.92
+118.76%
-26.25
-85.76%
-14.13
-171.71%
-5.20
Special Income Charges
-8.50
+25.24%
-11.37
-13.81%
-9.99
-92.10%
-5.20
Other Special Charges
8.50
-25.24%
11.37
+13.81%
9.99
+92.10%
5.20
Net Income
53.38
+198.95%
-53.95
-43.27%
-37.66
-14.47%
-32.90
Pretax Income
-15.86
+65.02%
-45.34
-9.99%
-41.22
-14.03%
-36.15
Net Non Operating Interest Income Expense
0.40
+144.44%
-0.90
+84.47%
-5.80
-13.25%
-5.12
Interest Expense Non Operating
—
0.90
-84.47%
5.80
+13.25%
5.12
Net Interest Income
0.40
+144.44%
-0.90
+84.47%
-5.80
-13.25%
-5.12
Interest Expense
—
0.90
-84.47%
5.80
+13.25%
5.12
Interest Income Non Operating
0.40
—
—
—
Interest Income
0.40
—
—
—
Other Income Expense
2.17
+108.65%
-25.06
-68.32%
-14.89
-1330.16%
-1.04
Other Non Operating Income Expenses
-2.76
-332.55%
1.19
+256.26%
-0.76
-118.25%
4.16
Gain On Sale Of Security
13.42
+190.23%
-14.88
-259.37%
-4.14
—
Tax Provision
0.01
+85.71%
0.01
-75.00%
0.03
-17.65%
0.03
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
1.03
+118.76%
-5.51
-85.76%
-2.97
-171.71%
-1.09
Net Income Including Noncontrolling Interests
53.38
+198.95%
-53.95
-43.27%
-37.66
-14.47%
-32.90
Net Income From Continuing Operation Net Minority Interest
-15.87
+65.00%
-45.34
-9.93%
-41.25
-14.00%
-36.18
Net Income From Continuing And Discontinued Operation
53.38
+198.95%
-53.95
-43.27%
-37.66
-14.47%
-32.90
Net Income Continuous Operations
-15.87
+65.00%
-45.34
-9.93%
-41.25
-14.00%
-36.18
Net Income Discontinuous Operations
69.25
+904.87%
-8.60
-339.47%
3.59
+9.38%
3.29
Normalized Income
-19.76
+19.70%
-24.61
+18.20%
-30.09
+6.19%
-32.07
Net Income Common Stockholders
53.38
+198.95%
-53.95
-43.27%
-37.66
-14.47%
-32.90
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
0.87
+146.77%
-1.86
+10.14%
-2.07
+13.03%
-2.38
Basic EPS
1.29
+169.35%
-1.86
+10.14%
-2.07
+13.03%
-2.38
Basic Average Shares
41.42
+42.47%
29.07
+60.08%
18.16
+31.29%
13.83
Diluted Average Shares
45.94
+58.04%
29.07
+60.08%
18.16
+31.29%
13.83
Diluted NI Availto Com Stockholders
39.96
+174.06%
-53.95
-43.27%
-37.66
-14.47%
-32.90
Average Dilution Earnings
-13.42
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
62.35
+72.59%
36.13
-16.81%
43.43
-36.92%
68.84
Current Assets
55.82
+113.27%
26.17
-16.26%
31.25
-38.36%
50.70
Cash Cash Equivalents And Short Term Investments
36.35
+174.57%
13.24
-31.32%
19.28
+13.46%
16.99
Cash And Cash Equivalents
36.35
+174.57%
13.24
-31.32%
19.28
+13.46%
16.99
Cash Financial
—
—
—
16.99
Receivables
14.58
+107.22%
7.04
+18.07%
5.96
-66.12%
17.59
Accounts Receivable
1.73
-23.81%
2.28
-30.25%
3.26
-13.54%
3.77
Gross Accounts Receivable
1.93
-32.75%
2.88
-27.43%
3.96
+2.30%
3.87
Allowance For Doubtful Accounts Receivable
-0.20
+66.67%
-0.60
+14.29%
-0.70
-600.00%
-0.10
Other Receivables
12.85
+169.87%
4.76
+76.56%
2.70
-80.48%
13.81
Inventory
2.62
+35.53%
1.93
-49.88%
3.85
-9.13%
4.24
Raw Materials
0.24
+251.47%
0.07
-71.90%
0.24
-62.88%
0.65
Work In Process
—
0.74
+158.74%
0.29
-47.13%
0.54
Finished Goods
2.38
+27.64%
1.86
-43.97%
3.33
+9.12%
3.05
Prepaid Assets
—
—
—
—
Restricted Cash
—
—
—
0.00
Assets Held For Sale Current
0.00
-100.00%
1.98
0.00
-100.00%
9.50
Other Current Assets
2.27
+14.35%
1.99
-8.27%
2.17
-9.30%
2.39
Total Non Current Assets
6.53
-34.38%
9.96
-18.23%
12.18
-32.89%
18.14
Net PPE
5.00
+488.59%
0.85
+68.65%
0.50
-10.80%
0.56
Gross PPE
5.29
+393.56%
1.07
-1.29%
1.08
-5.65%
1.15
Accumulated Depreciation
-0.28
-28.05%
-0.22
+61.96%
-0.58
+0.68%
-0.58
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.10
-16.26%
0.12
-56.07%
0.28
-76.99%
1.22
Construction In Progress
1.36
0.00
—
—
Other Properties
3.78
+343.31%
0.85
+19.50%
0.71
+204.85%
-0.68
Leases
0.04
-55.21%
0.10
+4.35%
0.09
-84.99%
0.61
Goodwill And Other Intangible Assets
1.53
-41.19%
2.60
-77.72%
11.67
-22.55%
15.07
Other Intangible Assets
1.53
-41.19%
2.60
-77.72%
11.67
-22.55%
15.07
Other Non Current Assets
—
6.50
—
2.51
Total Liabilities Net Minority Interest
34.68
-57.91%
82.39
+0.44%
82.03
+11.04%
73.87
Current Liabilities
25.14
-33.49%
37.80
-12.18%
43.04
+0.99%
42.62
Payables And Accrued Expenses
9.14
-18.75%
11.25
-11.23%
12.68
+14.16%
11.10
Payables
4.79
+15.47%
4.15
+30.02%
3.19
+40.33%
2.27
Accounts Payable
4.79
+15.47%
4.15
+30.02%
3.19
+132.24%
1.37
Other Payable
—
—
0.91
+0.67%
0.90
Current Accrued Expenses
4.35
-38.74%
7.10
-25.10%
9.48
+7.42%
8.83
Current Debt And Capital Lease Obligation
0.35
-74.55%
1.40
-61.21%
3.60
+1450.00%
0.23
Current Debt
—
1.25
-62.36%
3.32
—
Other Current Borrowings
—
1.25
-62.36%
3.32
—
Current Capital Lease Obligation
0.35
+144.83%
0.14
-47.27%
0.28
+18.53%
0.23
Current Deferred Liabilities
—
—
—
—
Current Deferred Revenue
—
—
—
—
Other Current Liabilities
15.64
-37.80%
25.15
-6.05%
26.77
-14.43%
31.28
Total Non Current Liabilities Net Minority Interest
9.54
-78.61%
44.59
+14.36%
38.99
+24.74%
31.26
Liabilities Heldfor Sale Non Current
0.00
-100.00%
0.41
0.00
-100.00%
0.96
Long Term Debt And Capital Lease Obligation
3.59
-84.14%
22.62
+11.12%
20.36
-16.09%
24.26
Long Term Debt
—
22.60
+11.04%
20.36
-16.09%
24.26
Long Term Capital Lease Obligation
3.59
+22318.75%
0.02
0.00
-100.00%
0.96
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Revenue
—
—
—
—
Other Non Current Liabilities
2.83
-48.49%
5.49
-6.55%
5.88
-2.78%
6.04
Stockholders Equity
27.67
+159.82%
-46.26
-19.84%
-38.60
-666.94%
-5.03
Common Stock Equity
27.67
+159.82%
-46.26
-19.84%
-38.60
-666.94%
-5.03
Capital Stock
0.04
+22.86%
0.04
+52.17%
0.02
+43.75%
0.02
Common Stock
0.04
+22.86%
0.04
+52.17%
0.02
+43.75%
0.02
Share Issued
42.78
+21.51%
35.21
+51.79%
23.20
+43.76%
16.14
Ordinary Shares Number
42.78
+21.51%
35.21
+51.79%
23.20
+43.76%
16.14
Additional Paid In Capital
203.84
+11.21%
183.30
+33.77%
137.02
+3.07%
132.94
Retained Earnings
-176.21
+23.25%
-229.59
-30.71%
-175.64
-27.29%
-137.99
Total Equity Gross Minority Interest
27.67
+159.82%
-46.26
-19.84%
-38.60
-666.94%
-5.03
Total Capitalization
27.67
+216.97%
-23.66
-29.67%
-18.24
-194.89%
19.23
Working Capital
30.68
+363.95%
-11.62
+1.37%
-11.78
-245.77%
8.08
Invested Capital
27.67
+223.50%
-22.41
-50.15%
-14.92
-177.61%
19.23
Total Debt
3.94
-83.58%
24.01
+0.26%
23.95
-2.20%
24.49
Net Debt
—
10.61
+141.17%
4.40
-39.47%
7.27
Capital Lease Obligations
3.94
+2348.45%
0.16
-41.45%
0.28
+18.53%
0.23
Net Tangible Assets
26.14
+153.51%
-48.86
+2.81%
-50.27
-150.08%
-20.10
Tangible Book Value
26.14
+153.51%
-48.86
+2.81%
-50.27
-150.08%
-20.10
Derivative Product Liabilities
3.12
-80.57%
16.08
+25.99%
12.76
0.00
Line Of Credit
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-44.81
-97.78%
-22.66
-4.12%
-21.76
-1.53%
-21.43
Cash Flow From Continuing Operating Activities
-44.81
-97.78%
-22.66
-4.12%
-21.76
-1.53%
-21.43
Net Income From Continuing Operations
53.38
+198.95%
-53.95
-43.27%
-37.66
-14.47%
-32.90
Depreciation Amortization Depletion
2.79
-19.30%
3.45
-7.92%
3.75
+0.40%
3.73
Depreciation And Amortization
2.79
-19.30%
3.45
-7.92%
3.75
+0.40%
3.73
Other Non Cash Items
2.23
+20.88%
1.85
-66.68%
5.55
+386.23%
-1.94
Stock Based Compensation
5.21
-33.92%
7.89
+223.80%
2.44
-33.18%
3.65
Asset Impairment Charge
0.46
-0.43%
0.46
-22.03%
0.59
0.00
Operating Gains Losses
-92.35
-728.30%
14.70
+533.70%
-3.39
-1189.71%
0.31
Gain Loss On Investment Securities
-13.42
-190.23%
14.88
+259.37%
4.14
—
Change In Working Capital
-16.53
-661.81%
2.94
-57.71%
6.96
+21.85%
5.71
Change In Receivables
-0.00
+99.87%
-1.54
-112.89%
11.92
+181.38%
-14.65
Changes In Account Receivables
0.08
-84.06%
0.53
-34.29%
0.80
+196.16%
-0.83
Change In Inventory
-1.64
-2729.31%
-0.06
+90.48%
-0.61
-22.29%
-0.50
Change In Prepaid Assets
-0.28
-138.36%
0.74
+344.91%
0.17
+110.94%
-1.53
Change In Payables And Accrued Expense
-6.55
-470.30%
-1.15
+45.67%
-2.11
-137.78%
5.59
Change In Other Working Capital
—
—
-0.07
+87.74%
-0.57
Change In Other Current Liabilities
-8.06
-263.04%
4.94
+305.44%
-2.41
-114.33%
16.79
Investing Cash Flow
78.56
+16673.63%
-0.47
-103.34%
14.21
+2731.11%
-0.54
Cash Flow From Continuing Investing Activities
78.56
+16673.63%
-0.47
-103.34%
14.21
+2731.11%
-0.54
Capital Expenditure
-1.88
-186.85%
-0.65
-89.02%
-0.35
+35.93%
-0.54
Capital Expenditure Reported
-1.88
-186.85%
-0.65
-89.02%
-0.35
+35.93%
-0.54
Net Business Purchase And Sale
80.44
+44586.11%
0.18
-98.76%
14.55
0.00
Gain Loss On Sale Of Business
-80.21
-44461.67%
-0.18
+97.61%
-7.53
0.00
Financing Cash Flow
-10.64
-162.23%
17.09
+73.72%
9.84
+15.29%
8.54
Cash Flow From Continuing Financing Activities
-10.64
-162.23%
17.09
+73.72%
9.84
+15.29%
8.54
Net Issuance Payments Of Debt
-23.06
-1053.20%
-2.00
-2.30%
-1.96
-220.53%
1.62
Issuance Of Debt
—
—
—
25.00
Repayment Of Debt
—
—
0.00
+100.00%
-4.76
Long Term Debt Issuance
—
—
—
25.00
Long Term Debt Payments
—
—
—
-18.61
Net Long Term Debt Issuance
-23.06
-1053.20%
-2.00
-2.30%
-1.96
-130.62%
6.38
Short Term Debt Payments
—
—
0.00
+100.00%
-4.76
Net Short Term Debt Issuance
—
—
0.00
+100.00%
-4.76
Net Common Stock Issuance
13.79
+11.34%
12.39
+22.86%
10.09
-0.04%
10.09
Proceeds From Stock Option Exercised
0.11
-99.30%
15.89
+7154.34%
0.22
-44.56%
0.40
Net Other Financing Charges
-1.48
+83.87%
-9.18
-715.90%
1.49
+141.75%
-3.57
Changes In Cash
23.11
+482.82%
-6.04
-363.97%
2.29
+117.02%
-13.44
Beginning Cash Position
13.24
-31.32%
19.28
+13.46%
16.99
-44.17%
30.43
End Cash Position
36.35
+174.57%
13.24
-31.32%
19.28
+13.46%
16.99
Free Cash Flow
-46.69
-100.27%
-23.31
-5.45%
-22.11
-0.61%
-21.97
Interest Paid Supplemental Data
7.49
+41.68%
5.29
+127.83%
2.32
-57.65%
5.48
Common Stock Issuance
13.79
+11.34%
12.39
+22.86%
10.09
-0.04%
10.09
Issuance Of Capital Stock
13.79
+11.34%
12.39
+22.86%
10.09
-0.04%
10.09
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
Sale Of Business
80.44
+44586.11%
0.18
-98.76%
14.55
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category